RecruitingPhase 1NCT06513819

HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)

Sponsor

Yale University

Enrollment

100 participants

Start Date

Jan 15, 2025

Study Type

INTERVENTIONAL

Conditions

Cannabis Use Alcohol Drinking HIV Fall

Summary

The focus of this pilot will be on falls and neurocognitive symptoms, and the impact of alcohol, cannabis use, and medications on these outcomes. The rationale is that alcohol use at any level may interact with neurocognitively active medications, alcohol, and cannabis use leading to falls and impaired cognition.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This pilot study is testing a pharmacist-led program to help HIV-positive veterans reduce risky medication combinations — specifically the use of multiple medications that interact with alcohol — and to help those who drink cut back safely. **You may be eligible if...** - You are HIV-positive and have visited a VA (Veterans Affairs) facility in the past year - You currently drink alcohol (based on a brief screening test called AUDIT-C) - You are taking 5 or more non-HIV medications, including at least one of: benzodiazepines, opioids, muscle relaxants, sleeping pills, or certain antidepressants (SSRIs) **You may NOT be eligible if...** - You are currently hospitalized as an inpatient - You have been diagnosed with an alcohol use disorder in the past 12 months - Your alcohol screening suggests moderate or severe alcohol use disorder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALInformation Motivation Behavioral and Motivational Interviewing (IMB-MI) technique

Delivered by a clinical pharmacist who will employ IMB-MI in informational, participant-centered discussions in which the clinical pharmacist and the participant collaboratively discuss the harms of alcohol use (with or without concurrent use of cannabis) and polypharmacy (specifically neurocognitively active medications), the relationship of these exposures to fall risk and NCEs, and how to mitigate these harms. Together pharmacist and participant will develop a plan for change in alcohol and polypharmacy use, self-monitoring, medications of concern, symptoms, and any additional resources needed. The goal of the intervention being to help patients stop or decrease alcohol use and stop medications in situations where it is safe to do so and agreed upon by the primary provider (but substitutions will be made if necessary).